Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apabetalone in healthy subjects and subjects with low HDL
NCT00768274Phase 2Completed
- Sponsor
- Resverlogix Corp.
- Start
- Sep 2008
- Primary completion
- Aug 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of apabetalone in dyslipidemia, atherosclerosis and cardiovascular disease (CVD) (3 arms), sponsored by Resverlogix Corp. Primary endpoints: Safety at 1 month, Pharmacokinetics at 1 month and 1 more. Started Sep 2008; status: completed.
02
Drugs
apabetalone
03
Conditions
dyslipidemiaatherosclerosiscardiovascular disease (CVD)
Beyond the preview
Go deeper on NCT00768274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00768274.